EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Automatic metabolic breast cancer staging using [¹⁸F]FDG PET/CT: comparison with nuclear medicine physician-based and clinical staging

Cláudia Santos Constantino iD, Carla Oliveira iD, Francisco P M Oliveira iD, Inês Moreira iD, Andrea DeCensi iD, Susana Vinga iD, Durval C Costa iD

European Journal of Nuclear Medicine and Molecular Imaging · 2026

DOI: 10.1007/s00259-026-08005-y ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift European Journal of Nuclear Medicine and Molecular Imaging, 2026. Verfasst von Cláudia Santos Constantino und 6 weiteren Autor:innen. Beteiligte Einrichtung: Champalimaud Clinical Centre, Champalimaud Foundation, Av. Brasília, Lisbon, 1400-038, Portugal. claudia.constantino@research.fchampalimaud.org. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Breast Neoplasms, Nuclear Medicine. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study aimed to evaluate a deep-learning (DL)-based framework to automatically perform breast cancer (BC) metabolic staging on [¹⁸F]FDG PET/CT, and to assess agreement among DL-based, nuclear medicine (NM) physician-based, and clinical staging.

Methods

A total of 403 histologically confirmed BC patients who underwent whole-body staging [¹⁸F]FDG PET/CT were retrospectively included. All [ 18 F]FDG avid lesions suspected of malignancy were segmented by an NM physician and classified into four key tumor regions: primary tumor (pT), regional axillary lymph nodes (ALN), extra-axillary locoregional nodes (extra-ALN), and distant metastases (dM). Data were split into training ( n = 303) and testing ( n = 100) sets using a stratified approach. Class-specific DL segmentation networks were developed. A post-processing pipeline was implemented to derive metabolic TNM staging from the DL-based segmentation. Using NM-based and clinical staging segmentation as reference, accuracy, sensitivity, and specificity were computed for T, N, and M. Segmentation performance was evaluated using the Dice coefficient (DC) and lesion detection (LD) metrics. NM-based metabolic staging was also compared with clinical staging.

Results

DL-based staging showed concordance with NM-based/clinical staging of 75/62%, 87/74%, and 83/82% for T, N, and M, respectively. For N3 (presence of extra-ALN) and M1 (presence of dM), where [¹⁸F]FDG PET/CT is particularly relevant, sensitivity/specificity of DL-based (NM-based reference) were 0.86/0.96, and 0.97/0.78, respectively. Segmentation performance was good to excellent for pT, ALN, and dM (median DC ≥ 0.83 and LD ≥ 0.78), and moderate for extra-ALN (median DC = 0.63 and LD ≥ 0.71). NM-based metabolic staging agreed with clinical staging in 63%, 80%, and 99% of cases for T, N, and M, respectively.

Conclusion

Although expert supervision remains essential, the developed DL-based framework demonstrates potential as a supportive tool for metabolic staging in BC patients, facilitating a workflow-efficient [¹⁸F]FDG PET/CT-based staging assessment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fluorodeoxyglucose F18Positron Emission Tomography Computed TomographyBreast NeoplasmsNuclear MedicinePhysiciansHumansNeoplasm StagingFemaleMiddle AgedRetrospective StudiesAutomationAgedAdultDeep LearningImage Processing, Computer-Assisted

Stichwörter der Autor:innen

Artificial intelligenceBreast cancer stagingComputer-assisted image analysis[¹⁸F]FDG PET/CT

Substanzen

Fluorodeoxyglucose F18

Autor:innen und Institutionen

  • Champalimaud Clinical Centre, Champalimaud Foundation, Av. Brasília, Lisbon, 1400-038, Portugal. claudia.constantino@research.fchampalimaud.org.
  • Instituto Superior Técnico, INESC-ID, Universidade de Lisboa, Lisbon, Portugal. claudia.constantino@research.fchampalimaud.org.
  • Champalimaud Clinical Centre, Champalimaud Foundation, Av. Brasília, Lisbon, 1400-038, Portugal.
  • Instituto Superior Técnico, INESC-ID, Universidade de Lisboa, Lisbon, Portugal.

ORCID-Profile: Cláudia Santos Constantino, Carla Oliveira, Francisco P M Oliveira, Inês Moreira, Andrea DeCensi, Susana Vinga, Durval C Costa

Förderung

  • Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud

Zitieren

APA

Constantino, C. S., Oliveira, C., Oliveira, F. P. M., Moreira, I., DeCensi, A., Vinga, S., & Costa, D. C. (2026). Automatic metabolic breast cancer staging using [¹⁸F]FDG PET/CT: comparison with nuclear medicine physician-based and clinical staging. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08005-y

Vancouver

Constantino CS, Oliveira C, Oliveira FPM, Moreira I, DeCensi A, Vinga S, et al. Automatic metabolic breast cancer staging using [¹⁸F]FDG PET/CT: comparison with nuclear medicine physician-based and clinical staging. European Journal of Nuclear Medicine and Molecular Imaging. 2026. doi:10.1007/s00259-026-08005-y

BibTeX
@article{Constantino2026,
  author = {Constantino, Cláudia Santos and Oliveira, Carla and Oliveira, Francisco P M and Moreira, Inês and DeCensi, Andrea and Vinga, Susana and Costa, Durval C},
  title = {Automatic metabolic breast cancer staging using [¹⁸F]FDG PET/CT: comparison with nuclear medicine physician-based and clinical staging},
  journal = {European Journal of Nuclear Medicine and Molecular Imaging},
  year = {2026},
  doi = {10.1007/s00259-026-08005-y}
}
Kostenlos starten →